참고문헌
- Ponikowski P, Anker SD, AlHabib KF, et al. Heart Failure Preventing Disease and Death Worldwide. Sophia Antipolis: European Society of Cardiology; 2014.
- Aizpuru F, Millan E, Garmendia I, Mateos M, Librero J. Hospitalizations for heart failure: epidemiology and health system burden based on data gathered in routine practice. Med Clinica Practica 2020;3:100140.
- Mesquita ET, Jorge AJ, Rabelo LM, Souza CV Jr. Understanding hospitalization in patients with heart failure. Int J Cardiovasc Sci 2017;30:81-90.
- Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res 2023;118:3272-87.
- Riello RJ III. Heart failure with reduced ejection fraction. In: Gale SM, ed. PSAP 2022 Book - Cardiology [Internet]. Lenexa: American College of Clinical Pharmacy; 2022 [cited 2023 April 15]. Available from: https://www.accp.com/docs/bookstore/psap/p2022b1_sample.pdf.
- Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail 2020;22:1342-56.
- Roger VL. Epidemiology of heart failure: a contemporary perspective. Circ Res 2021;128:1421-34.
- Park JJ, Lee CJ, Park SJ, et al. Heart failure statistics in Korea, 2020: a report from the Korean Society of Heart Failure. Int J Heart Fail 2021;3:224-36.
- Osenenko KM, Kuti E, Deighton AM, Pimple P, Szabo SM. Burden of hospitalization for heart failure in the United States: a systematic literature review. J Manag Care Spec Pharm 2022;28:157-67.
- European Heart Network. Heart Failure and Cardiovascular Diseases - A European Heart Network Paper. Brussels: European Heart Network; 2019.
- Lee H, Oh SH, Cho H, Cho HJ, Kang HY. Prevalence and socioeconomic burden of heart failure in an aging society of South Korea. BMC Cardiovasc Disord 2016;16:215.
- Riley JP, Masters J. Practical multidisciplinary approaches to heart failure management for improved patient outcome. Eur Heart J Suppl 2016;18:G43-52.
- Morton G, Masters J, Cowburn PJ. Multidisciplinary team approach to heart failure management. Heart 2018;104:1376-82.
- de Araujo BC, de Melo RC, de Bortoli MC, Bonfim JR, Toma TS. How to prevent or reduce prescribing errors: an evidence brief for policy. Front Pharmacol 2019;10:439.
- Neu R, Leonard MA, Dehoorne ML, Scalia SJ, Kale-Pradhan PB, Giuliano CA. Impact of pharmacist involvement in heart failure transition of care. Ann Pharmacother 2020;54:239-46.
- Shah SP, Dixit NM, Mendoza K, et al. Integration of clinical pharmacists into a heart failure clinic within a safety-net hospital. J Am Pharm Assoc (2003) 2022;62:575-579.e2.
- Heart Online. Adverse drug reactions and heart failure. Sydney: National Heart Foundation of Australia; 2014.
- Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e895-1032.
- Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med 2020;382:1883-93.
- Sizar O, Podder V, Talati R. Empagliflozin. Treasure Island: StatPearls Publishing; 2023.
- Food and Drug Administration. Highlights of Prescribing Information: Dapagliflozin. Silver Spring: Food and Drug Administration; 2021.
- Bazroon AA, Alrashidi NF. Bisoprolol [Internet]. Treasure Island: StatPearl Publications; 2022 [cited 2023 April 14]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK551623/.
- Food and Drug Administration. Highlights of Prescribing Information: Coreg (Carvedilol) [Internet]. Silver Spring: Food and Drug Administration; 1995 [cited 2023 April 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020297s038lbl.pdf.
- Food and Drug Administration. Metoprolol Succinate [Internet]. Silver Spring: Food and Drug Administration; 2006 [cited 2023 April 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/019962s032lbl.pdf.
- Patibandla S, Heaton J, Kyaw H. Spironolactone. Treasure Island: StatPearls Publishing; 2022.
- Sharma A, Verma S, Bhatt DL, et al. Optimizing foundational therapies in patients with HFrEF: how do we translate these findings into clinical care? JACC Basic Transl Sci 2022;7:504-17.
- Stough WG, Patterson JH. Role and value of clinical pharmacy in heart failure management. Clin Pharmacol Ther 2017;102:209-12.
- Unverzagt S, Meyer G, Mittmann S, Samos FA, Unverzagt M, Prondzinsky R. Improving treatment adherence in heart failure. Dtsch Arztebl Int 2016;113:423-30.
- Cheng JW. Current perspectives on the role of the pharmacist in heart failure management. Integr Pharm Res Pract 2018;7:1-11.
- Hargraves TL, Bennet AA, Brien JE. Developing an outpatient heart failure pharmacy service. J Pharm Pract Res 2008;38:13-6.
- Schumacher PM, Becker N, Tsuyuki RT, et al. The evidence for pharmacist care in outpatients with heart failure: a systematic review and meta-analysis. ESC Heart Fail 2021;8:3566-76.
- Davis EM, Packard KA, Jackevicius CA. The pharmacist role in predicting and improving medication adherence in heart failure patients. J Manag Care Spec Pharm 2014;20:741-55.
- Page RL 2nd, O'Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation 2016;134:e32-69.
- Hargraves TL, Bennett AA, Brien JE. Evaluating outpatient pharmacy services: a literature review of specialist heart failure services. Int J Pharm Pract 2010;14:3-9.
- Wang C, Lin Z, Miao D, et al. Dose titration of sacubitril/valsartan for heart failure with reduced ejection fraction: a real-world study. ESC Heart Fail 2023;10:1961-71.
- Speranza-Sanchez M, Zavaleta-Monestel E, Sancho-Zumbado S, Arguedas-Chacon S, Quiros-Romero A. From end-of-life care to improved quality of life and better prognosis by using vericiguat: a case report from Costa Rica. Cureus 2023;15:e39570.
- Gheorghiade M, Greene SJ, Butler J, et al. Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: the SOCRATES-REDUCED randomized trial. JAMA 2015;314:2251-62.
- Gattis WA, Hasselblad V, Whellan DJ, O'Connor CM. Reduction in heart failure events by the addition of a clinical pharmacist to the heart failure management team: results of the Pharmacist in Heart Failure Assessment Recommendation and Monitoring (PHARM) study. Arch Intern Med 1999;159:1939-45.
- Omboni S, Caserini M. Effectiveness of pharmacist's intervention in the management of cardiovascular diseases. Open Heart 2018;5:e000687.
- Lynch KA, Ganz DA, Saliba D, Chang DS, de Peralta SS. Improving heart failure care and guideline-directed medical therapy through proactive remote patient monitoring-home telehealth and pharmacy integration. BMJ Open Qual 2022;11:e001901.
- Lugo Zamora IL, Lloyd C, Lorenzo-Castro S, Mussenden C, Hale G. Utilizing pharmacist-led telehealth services in ambulatory patients with heart failure. Innov Pharm 2023;14:12.
- Mohammad RA, Betthauser KD, Korona RB, et al. Clinical pharmacist services within intensive care unit recovery clinics: an opinion of the critical care practice and research network of the American College of Clinical Pharmacy. JACCP J Am Coll Clin Pharm. 2020;3:1369-79.
- Rommers MK, Teepe-Twiss IM, Guchelaar HJ. Preventing adverse drug events in hospital practice: an overview. Pharmacoepidemiol Drug Saf 2007;16:1129-35.
- Gabay M, Spencer SH. Drug interactions: scientific and clinical principles. In: Beckett RD, ed. PSAP 2021 Book 3 - Chronic Conditions and Public Health PSAP [Internet]. Lenexa: American College of Clinical Pharmacy; 2021 [cited 2023 May 29]. Available from: https://www.accp.com/docs/bookstore/psap/p2021b3_sample.pdf.
- American College of Clinical Pharmacy. Comprehensive medication management in team-based care [Internet]. Lenexa: American College of Clinical Pharmacy; [cited 2023 May 30]. Available from: https://www.pcpcc.org/sites/default/files/event-attachments/CMM%20Brief.pdf.
- Luisetto M. Intensive care units (ICU): the clinical pharmacist role to improve clinical outcomes and reduce mortality rate - an undeniable function. J Clin Intensive Care Med 2017;2:49-56.
- Anderson SL, Marrs JC. A review of the role of the pharmacist in heart failure transition of care. Adv Ther 2018;35:311-23.
- Guerrero KS, Puls SE, Andrew DA. Transition of care and the impact on the environment care. J Nurs Educ Pract 2014;4:30-6.
- Layman SN, Elliott WV, Regen SM, Keough LA. Implementation of a pharmacist-led transitional care clinic. Am J Health Syst Pharm 2020;77:966-71.
- Garcia CG. A literature review of heart failure transitional care interventions. Am J Accountable Care 2017;5:21-5.
- Baecker A, Meyers M, Koyama S, et al. Evaluation of a transitional care program after hospitalization for heart failure in an integrated health care system. JAMA Netw Open 2020;3:e2027410.
- Mai Ba H, Son YJ, Lee K, Kim BH. Transitional care interventions for patients with heart failure: an integrative review. Int J Environ Res Public Health 2020;17:2925.
- Albert NM, Barnason S, Deswal A, et al. Transitions of care in heart failure: a scientific statement from the American Heart Association. Circ Heart Fail 2015;8:384-409.
- Amabile CM, Spencer AP. Keeping your patient with heart failure safe: a review of potentially dangerous medications. Arch Intern Med 2004;164:709-20.
- Sorensen A. An evaluation of the impact of clinical pharmacists on care transitions in a non-integrated healthcare system [dissertation]. Los Angeles: University of California, Los Angeles; 2018.